Telomir Pharmaceuticals Raises $1M At $7 Per Share In No-warrant, Restricted Common Stock Deal - Filing
Telomir Pharmaceuticals Raises $1M At $7 Per Share In No-warrant, Restricted Common Stock Deal - Filing
Telomir制药以每股7美元的价格在无认购权、受限普通股交易中筹集了100万美元 - 提交文件
On December 9, 2024, Telomir entered into a Stock Purchase Agreement with a certain accredited investor, pursuant to which the Company issued 142,857 shares of common stock at a price of $7 per share for a total of $1 million, a 20% premium to the closing price of the Company's common stock on the date of the transaction.
在2024年12月9日，Telomir与某位认证投资者签订了一项股票购买协议，根据该协议，公司以每股7美元的价格发行了142,857股普通股，总金额为100万美元，相当于公司普通股在交易日收盘价的20%的溢价。
The transaction did not involve the issuance of any warrants. This transaction follows a $5 million non-dilutive line of credit extended to the Company earlier this year by the same accredited investor, which remains undrawn to date.
此次交易并未涉及任何Warrants的发行。此次交易是在今年早些时候由同一认证投资者向公司提供的500万美元非稀释性信用额度之后进行的，该额度至今未被提款。
热门讨论
中概股财报季火热：惊喜盈利能否延续涨势？
1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？
Moomoo News Global
03/04 23:26
中国两会：会议前后股票价格走势的主要要点